Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease
businesswire.com
YARW
VYNE
The article announces the closing of a merger between Yarrow Bioscience and VYNE Therapeutics. No specific performance or outlook for VYNE is mentioned, only its role in the merger.